[ad_1]
JawaPos.com – The experimental antiviral drug remdesivir produced by Gilead Sciences Inc. is said to help cure symptoms in patients with Covid-19. Gilead said the drug would be effective when first administered to patients with Covid-19.
The drug, which is now closely monitored, has hit the market in recent weeks. It also caused Gilead’s shares to rise 9 percent. In the Gilead study, 62 percent of remdesivir-treated patients were able to get home from the hospital faster than 49 percent of late-treated patients.
Also read: The more aggressive the mutated corona virus is, the more severe the patient’s condition is.
Gilead is currently conducting a clinical trial of remdesivir in hospitalized patients with Covid-19 that is classified as severe. Attention to Gilead production drugs is very high because there is currently no approved treatment or preventive Covid-19 vaccine. Doctors now desperately need anything that can reduce the worst risk for patients exposed to Covid-19.
Meanwhile, the World Health Organization (WHO), which continues to search for and test vaccines for Covid-19, is reluctant to comment on remdesivir drugs that are said to be effective for patients when administered before. WHO said more data was needed on this matter.
“I don’t want to give specific comments on that (remdesivir). Because I haven’t read the report in detail,” said Dr. Mike Ryan, Head of the WHO Emergency Program at a press conference as reported by Reuters.
He also said the WHO could take a series of reports to determine the efficacy of a drug. “Obviously, we have ongoing randomized control trials in the UK and in the US, trials with the WHO. Remdesivir is one of the drugs seen in many of these trials. So I think more data will come out. At the moment, we haven’t commented much, “he said.
“We just hope that this drug (remdesivir) and other drugs have been shown to be helpful in the Covid-19 treatment effort,” added Ryan.
Watch the following interesting videos:
